search
Back to results

A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
LCI699-matching placebo
LCI699
Sponsored by
Novartis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Blood Pressure, Hypertension, Cortisol

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of hypertension with blood pressure ≥ 140/90 millimeters of mercury (mmHg) and < 180/110 mmHg on current antihypertensive treatment
  • Male and female participants 18-75 years of age
  • Participants must weigh at least 50 kilograms (kg)

Exclusion Criteria:

  • Recent history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebral accident or transient ischemic attack
  • Clinically significant electrocardiography (ECG) findings related to cardiac conduction defects
  • Type 1 diabetes or uncontrolled type 2 diabetes (haemoglobin A1c [HbA1c] > 9%)
  • Malignancies within the last 5 years (excluding basal cell skin cancer)
  • Liver disease

Other protocol-defined inclusion/exclusion criteria may apply.

Sites / Locations

  • Impact Clinical Trials
  • Associated Pharmaceutical Research Center, Inc
  • Innovative Clinical Research, Inc
  • Long Beach Center for Clinical Research
  • Metro Clinical Research
  • Clinical Study Center of Asheville, LLC
  • Northstate Clinical Research
  • Tipton Medical & Diagnostic Center
  • Punzi Medical Center
  • dgd Research, Inc
  • Encode Clinic

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

Cohort A: LCI699 0.5 mg QD

Cohort A: LCI699 1.0 mg QD

Cohort B1: LCI699 1.0 mg BID

Cohort B1: LCI699 2.0 mg QD

Placebo

Arm Description

Participants received LCI699 0.5 mg, capsules, orally, once daily (QD), with or without food for up to 6 weeks.

Participants received LCI699 1.0 mg, capsules, orally, QD, with or without food for up to 6 weeks.

Participants received LCI699 1.0 mg, capsules, orally, twice daily (BID), with or without food for up to 6 weeks.

Participants received LCI699 2.0 mg, capsules, orally, QD, with or without food for up to 6 weeks.

Participants received LCI699-matching placebo, capsules, orally, QD or BID, with or without food for up to 6 weeks.

Outcomes

Primary Outcome Measures

Maximum Tolerated Dose (MTD) of LCI699 With Respect to Effect on the Adrenocorticotropic Hormone (ACTH)-Stimulated Cortisol Response Following ACTH Stimulation in Hypertensive Participants
As per the protocol, MTD is the dose at which 4 participants exhibited ACTH-stimulated cortisol results <400 nanomoles per liter (nmol/L). The change in the distribution across the treatments were analyzed using 1- way analysis of variance (ANOVA) for continuous variables.

Secondary Outcome Measures

LCI699 Exposure-response Relationship on Cortisol Levels Following ACTH Stimulation in Hypertensive Participants
Exposure-response relationship was assessed using ACTH stimulation test. Tests were done 2 hours after study drug administration (i.e., at peak LCI699 concentrations). An increase in cortisol greater than >500 nmol at 60 minutes after ACTH administration was expected.
LCI699 Plasma Concentration Post LCI699 Administration at Day 7
Maximum Plasma Concentration (Cmax) of LCI699
Time of Maximum Plasma Concentration (Tmax) of LCI699
Area Under the Concentration Time Curve From Time 0 to 8 Hours Post LCI699 Administration (AUC0-8)
Area Under the Concentration Time Curve Over the Dosing Interval (AUC0-τ) for LCI699
Apparent Terminal Half-life (T1/2) of LCI699
Number of Participants With Adverse Event (AEs)
An AE is an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives.
Percentage of Participants With a Mean Sitting Systolic Blood Pressure (MSSBP) Response and MSSBP Control at Week 6 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)
Automated arterial BP determinations was made with an automated BP device (such as the Omron BP monitor) in accordance with the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV. Sitting and standing blood pressure (BP) and heart rate (HR) measurements were performed. MSSBP response was defined as the percentage of participants with a MSSBP <140 mmHg or a >=20 mmHg reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP <140 mmHg for non-diabetic participants and <130mHg for diabetic participants.
Percentage of Participants With a Mean Sitting Diastolic Blood Pressure (MSDBP) Response and MSDBP Control at Week 6 LOCF, as Measured by OBP
Automated arterial BP determinations was made with an automated BP device (such as the Omron BP monitor) in accordance with the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV. Sitting and standing BP and HR measurements were performed. MSDBP response was defined as the percentage of participants with a MSDBP <90 mmHg or a >= 10 mmHg reduction from baseline. MSDBP control was defined as the percentage of participants with a MSDBP <90 mmHg for non-diabetic participants and <80mHg for diabetic participants.

Full Information

First Posted
January 5, 2009
Last Updated
May 6, 2021
Sponsor
Novartis
Collaborators
Great Lakes Drug Development, Inc., Integrium
search

1. Study Identification

Unique Protocol Identification Number
NCT00817414
Brief Title
A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension
Official Title
A Phase II, Randomized, Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Effects of LCI699 on Cortisol in Patients With Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
January 14, 2009 (Actual)
Primary Completion Date
August 12, 2009 (Actual)
Study Completion Date
August 12, 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis
Collaborators
Great Lakes Drug Development, Inc., Integrium

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study determined the maximum dose of LCI6999 with respect to effect on the ACTH-stimulated cortisol response in participants with hypertension.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Blood Pressure, Hypertension, Cortisol

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Sequential Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
63 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cohort A: LCI699 0.5 mg QD
Arm Type
Experimental
Arm Description
Participants received LCI699 0.5 mg, capsules, orally, once daily (QD), with or without food for up to 6 weeks.
Arm Title
Cohort A: LCI699 1.0 mg QD
Arm Type
Experimental
Arm Description
Participants received LCI699 1.0 mg, capsules, orally, QD, with or without food for up to 6 weeks.
Arm Title
Cohort B1: LCI699 1.0 mg BID
Arm Type
Experimental
Arm Description
Participants received LCI699 1.0 mg, capsules, orally, twice daily (BID), with or without food for up to 6 weeks.
Arm Title
Cohort B1: LCI699 2.0 mg QD
Arm Type
Experimental
Arm Description
Participants received LCI699 2.0 mg, capsules, orally, QD, with or without food for up to 6 weeks.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants received LCI699-matching placebo, capsules, orally, QD or BID, with or without food for up to 6 weeks.
Intervention Type
Drug
Intervention Name(s)
LCI699-matching placebo
Intervention Description
LCI699-matching placebo oral capsules
Intervention Type
Drug
Intervention Name(s)
LCI699
Intervention Description
LCI699 oral capsules
Primary Outcome Measure Information:
Title
Maximum Tolerated Dose (MTD) of LCI699 With Respect to Effect on the Adrenocorticotropic Hormone (ACTH)-Stimulated Cortisol Response Following ACTH Stimulation in Hypertensive Participants
Description
As per the protocol, MTD is the dose at which 4 participants exhibited ACTH-stimulated cortisol results <400 nanomoles per liter (nmol/L). The change in the distribution across the treatments were analyzed using 1- way analysis of variance (ANOVA) for continuous variables.
Time Frame
Up to Week 6
Secondary Outcome Measure Information:
Title
LCI699 Exposure-response Relationship on Cortisol Levels Following ACTH Stimulation in Hypertensive Participants
Description
Exposure-response relationship was assessed using ACTH stimulation test. Tests were done 2 hours after study drug administration (i.e., at peak LCI699 concentrations). An increase in cortisol greater than >500 nmol at 60 minutes after ACTH administration was expected.
Time Frame
Up to Week 6
Title
LCI699 Plasma Concentration Post LCI699 Administration at Day 7
Time Frame
Predose and 3 hours post-dose on Day 7
Title
Maximum Plasma Concentration (Cmax) of LCI699
Time Frame
Days 7, 28: Pre-dose and 3 hours post-dose; Day 30: Pre-dose; Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose
Title
Time of Maximum Plasma Concentration (Tmax) of LCI699
Time Frame
Days 7, 28: Pre-dose and 3 hours post-dose; Day 30: Pre-dose; Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose
Title
Area Under the Concentration Time Curve From Time 0 to 8 Hours Post LCI699 Administration (AUC0-8)
Time Frame
Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose
Title
Area Under the Concentration Time Curve Over the Dosing Interval (AUC0-τ) for LCI699
Time Frame
Days 7, 28: Pre-dose and 3 hours post-dose; Day 30: Pre-dose; Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose
Title
Apparent Terminal Half-life (T1/2) of LCI699
Time Frame
Days 7, 28: Pre-dose and 3 hours post-dose; Day 30: Pre-dose; Day 42: Pre-dose and 0.5, 1, 2, 3, 4, and 8-hours post-dose
Title
Number of Participants With Adverse Event (AEs)
Description
An AE is an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives.
Time Frame
Up to 8 weeks
Title
Percentage of Participants With a Mean Sitting Systolic Blood Pressure (MSSBP) Response and MSSBP Control at Week 6 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)
Description
Automated arterial BP determinations was made with an automated BP device (such as the Omron BP monitor) in accordance with the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV. Sitting and standing blood pressure (BP) and heart rate (HR) measurements were performed. MSSBP response was defined as the percentage of participants with a MSSBP <140 mmHg or a >=20 mmHg reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP <140 mmHg for non-diabetic participants and <130mHg for diabetic participants.
Time Frame
Week 6
Title
Percentage of Participants With a Mean Sitting Diastolic Blood Pressure (MSDBP) Response and MSDBP Control at Week 6 LOCF, as Measured by OBP
Description
Automated arterial BP determinations was made with an automated BP device (such as the Omron BP monitor) in accordance with the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV. Sitting and standing BP and HR measurements were performed. MSDBP response was defined as the percentage of participants with a MSDBP <90 mmHg or a >= 10 mmHg reduction from baseline. MSDBP control was defined as the percentage of participants with a MSDBP <90 mmHg for non-diabetic participants and <80mHg for diabetic participants.
Time Frame
Week 6

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of hypertension with blood pressure ≥ 140/90 millimeters of mercury (mmHg) and < 180/110 mmHg on current antihypertensive treatment Male and female participants 18-75 years of age Participants must weigh at least 50 kilograms (kg) Exclusion Criteria: Recent history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebral accident or transient ischemic attack Clinically significant electrocardiography (ECG) findings related to cardiac conduction defects Type 1 diabetes or uncontrolled type 2 diabetes (haemoglobin A1c [HbA1c] > 9%) Malignancies within the last 5 years (excluding basal cell skin cancer) Liver disease Other protocol-defined inclusion/exclusion criteria may apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Impact Clinical Trials
City
Beverly Hills
State/Province
California
ZIP/Postal Code
90211
Country
United States
Facility Name
Associated Pharmaceutical Research Center, Inc
City
Buena Park
State/Province
California
ZIP/Postal Code
90620
Country
United States
Facility Name
Innovative Clinical Research, Inc
City
Harbor City
State/Province
California
ZIP/Postal Code
90710
Country
United States
Facility Name
Long Beach Center for Clinical Research
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Facility Name
Metro Clinical Research
City
Littleton
State/Province
Colorado
ZIP/Postal Code
80120
Country
United States
Facility Name
Clinical Study Center of Asheville, LLC
City
Asheville
State/Province
North Carolina
ZIP/Postal Code
28801
Country
United States
Facility Name
Northstate Clinical Research
City
Lenoir
State/Province
North Carolina
ZIP/Postal Code
28645
Country
United States
Facility Name
Tipton Medical & Diagnostic Center
City
Tipton
State/Province
Pennsylvania
ZIP/Postal Code
16684
Country
United States
Facility Name
Punzi Medical Center
City
Carrollton
State/Province
Texas
ZIP/Postal Code
75006
Country
United States
Facility Name
dgd Research, Inc
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Encode Clinic
City
Reykjavik
State/Province
SA
Country
Iceland

12. IPD Sharing Statement

Citations:
PubMed Identifier
24107737
Citation
Schumacher CD, Steele RE, Brunner HR. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. J Hypertens. 2013 Oct;31(10):2085-93. doi: 10.1097/HJH.0b013e328363570c.
Results Reference
derived

Learn more about this trial

A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension

We'll reach out to this number within 24 hrs